NTMir - NTM Info and Research, Inc.
Donate
About Us
Patient Support
Medical & Science
News & Events

Clofazimine

Lamprene (generic name clofazimine) manufactured by Novartis, has not been available through traditional pharmaceutical distribution since October 2004. NTMir became aware of this situation when we received urgent calls from NTM patients, their healthcare providers who were notified that they would be unable to obtain the drug for the treatment of Mycobacterium avium-complex (MAC) infections, and by postings on the www.ntminfo.org patient support message board. Resolution of this situation was prioritized by NTMir because we are aware that in some patients with highly resistant MAC, clofazimine provides the only hope for adequate treatment and, in some cases, their survival.

NTMir investigation uncovered the reason that Novartis changed its distribution network and immediately began negotiating access for NTM patients.

In the desire to implement an international compassionate care program Novartis determined with the World Health Organization and the U.S. Department of Health and Human Services (DHHS) that clofazimine would only be available for the treatment of Hansen’s Disease. In addition, a decision was made that Clofazimine would be made available under special circumstances for use in the treatment of multi-drug resistant tuberculosis. Novartis notified physicians and set the date of November 1, 2004 to discontinue distribution to all entities with the exception of DHHS, which was implementing the new program. Novartis was unaware that clofazimine was medically essential in the treatment of MAC in certain NTM patients.

We are pleased to tell you that on behalf of NTM patients, NTMir has facilitated a special relationship with Novartis, the U.S. Department of Health and Human Services, and the U.S. Food and Drug Administration. As of 2005, a simple government program is in place to expedite access to clofazimine for NTM patients. This program will allow healthcare providers treating NTM and specifically Mycobacterium avium-complex infections in HIV seronegative patients to fill out a simple form and receive clofazimine.

The Process to Obtain Clofazimine 
The healthcare provider goes through their hospital Independent Review Board and then submits an individual IND to the FDA for the patient requiring the drug. 

Required Documents
FDA Forms:
   1571
   1572
   HFD-590
Doctor's CV
Current lab results for the patient (CBC, chem)
Signed informed consent document
IRB approval letter

For your information - Clofazimine Treatment Protocol

You do not need to contact Novartis. 
Once you have gone through the IRB and sent your forms to the FDA and you are approved, the clofazamine will be provided to your patient through Hansen's Division/Novartis free of cost - it usually takes about 10-14 days from the time the FDA receives your fax to when the clofazimine arrives.
Fax the forms to:
Ramou Mauer
Phone (301) 796-3928
Fax: (301) 796-9881
You may also need to mail the application to:
Division of Special Pathogen and Transplant Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Avenue
Building 22, Room 6170
Silver Spring, Maryland 20993


Please read the highlighted paragraph CAREFULLY.  We do not have any other information at this time.  If you have questions, it is best to contact the FDA at the numbers listed above.

NTMir is dedicated to improving knowledge about NTM disease and to promoting better care through partnerships between patients, providers, industry and government.

We appreciate the opportunity to serve you.

Philip Leitman
President

Miriam O'Day
Senior Director Public Policy

faq

press

support

donate

Join our email list.

Read our FAQs.  Learn more about pulmonary NTM disease and why it may affect you or someone you know.

New! Support Health Care Reform

New! Treatment Research

Participants Needed! Three Research Opportunities

NTM Nutrition Guide

find_us_on_facebook_badge.gif

Take a look at our
Events Calendar 

Free online support group


follow ntmir at http://twitter.com

Your donations support patients and achieve advances in research and education.

>> learn more

>> learn more

>> register / login

>> learn more

Home | Donate | Privacy Policy | About Us | Contact Us

‘NTMir’, ‘NTM Info & Research’, ‘NTMir Nontuberculous Mycobacteria NTM Info & Research, Inc.’, ‘Rapid Info Pilot Studies’, and ‘RIPS’ are trademarks or common law marks of NTM Info & Research, Inc.

© NTM Info & Research, Inc., 2008, All rights reserved.